Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer
1 October 2012 | By Roche
Final results from the Phase III HERA trial...
List view / Grid view
News
Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
New head of BASF unit Pharma Ingredients & Services
1 October 2012 | By BASF
As of October 1, Scott Thomson will assume the role of Senior Vice President...
Bristol-Myers Squibb appoints Frances Heller Senior Vice President, Business Development
28 September 2012 | By Bristol-Myers Squibb Company
Frances Heller will join as Senior VP, Business Development, on October 1...
Abbott’s HUMIRA® (adalimumab) receives U.S. FDA approval for the treatment of adult patients with moderate to severe ulcerative colitis
28 September 2012 | By Abbott
The U.S. FDA has approved HUMIRA®...
Avacta extends Pall Life Sciences’ Optim 1000 distribution agreement to include India
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
Europe’s largest biopharmaceutical company endorses CI SADE weight sorters
27 September 2012 | By CI Precision
Actelion Pharmaceuticals Ltd, has endorsed CI SADE weight sorters...
GlaxoSmithKline plc announces changes to its Board and Committees
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
GSK and Theravance announce FDA acceptance of FF/VI NDA submission in the US for COPD
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
Cisbio Bioassays launches epigenetics toolbox
25 September 2012 | By Cisbio Bioassays
Cisbio Bioassays announces the launch of its epigenetics toolbox for use in drug discovery research...
New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…
Inside Raman seminars at the STFC, Rutherford Appleton Laboratory, 11th and 12th September
24 September 2012 | By Renishaw plc
Celebrating 20 years of Renishaw Raman...
Novo Nordisk opens new research and development centre in China
24 September 2012 | By Novo Nordisk
Novo Nordisk invests an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing....
Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer
24 September 2012 | By
Data on 13 of its investigational and approved products will be presented at ESMO 2012...
CHMP recommends indication for the use of Trajenta® (linagliptin) tablets
24 September 2012 | By Boehringer Ingelheim / Eli Lilly and Company
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a Positive Opinion from the European Medicines Agency’s (EMA) medicinal committee recommending expanding the therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin). If approved by the European Commission, this will expand the indicated use of Trajenta® by…
